Close Menu

NEW YORK (GenomeWeb) – Tangen Biosciences today announced that it has closed a $9 million Series A equity financing round and will use the proceeds to develop its TangenDx platform for two undisclosed infectious disease tests performed in the clinic.

Tangen said that its platform employs rapid isothermal nucleic acid detection of targeted DNAs and RNAs directly from specimens. The platform may enable use of low cost, portable, and rapid MDx diagnostic capabilities outside traditional laboratories, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.